Girgert R, Schweizer P, Bock I, Narr R, Bruchelt G
Department of Pediatric Surgery, Klinikum Schnarrenberg, University of Tübingen, Germany.
J Cancer Res Clin Oncol. 1995;121(5):262-6. doi: 10.1007/BF01209591.
The thioether lysophospholipid BM 41.440 proved to be toxic against cells of two neuroblastoma cell lines in a dose- and time-dependent manner. The ID50 estimated in three different in vitro test systems declined from about 10 micrograms/ml after 24 h to 1 microgram/ml after a 1-week treatment of the neuroblastoma cells. These values are comparable to the ID50 found for neoplastic cells derived from other tissues. In comparison, hematopoietic progenitor cells (granulocyte/monocyte-colony-forming units) proved to be less sensitive to short-term treatment with BM 41.440. After long exposure to this drug the selectivity towards neuroblastoma cells decreased. This observation makes it unlikely that BM 41.440 can be used for treatment of neoplasia such as neuroblastoma, because only short-term treatment is acceptable considering the high bone marrow toxicity.
硫醚溶血磷脂BM 41.440被证明对两种神经母细胞瘤细胞系的细胞具有剂量和时间依赖性毒性。在三种不同的体外测试系统中估计的半数抑制浓度(ID50)在对神经母细胞瘤细胞进行24小时处理后约为10微克/毫升,而在经过1周处理后降至1微克/毫升。这些值与从其他组织衍生的肿瘤细胞的ID50相当。相比之下,造血祖细胞(粒细胞/单核细胞集落形成单位)被证明对BM 41.440的短期处理不太敏感。长期接触这种药物后,对神经母细胞瘤细胞的选择性降低。这一观察结果使得BM 41.440不太可能用于治疗神经母细胞瘤等肿瘤,因为考虑到高骨髓毒性,仅短期治疗是可接受的。